Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 325-333

  Kondapaneni, Muralidhar ^a   McGregor, John R ^a   Salvemini, Daniela ^b   Laubach, Victor E ^c   Samlowski, Wolfram E ^a,d  

^a UNIVERSITY OF UTAH   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NEVADA CANCER INSTITUTE   (United States)

Author keywords

Cytokines; Inducible nitric oxide synthase; iNOS knockout mice; Interleukin 2 (IL 2); Nitric oxide

Indexed keywords

ARGINASE; ARGININE DERIVATIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; LYSINE DERIVATIVE; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); PEROXYNITRITE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; C57BL 6 MOUSE; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HYPOTENSION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; URINARY EXCRETION;

ANIMALS; CAPILLARY LEAK SYNDROME; CAPILLARY PERMEABILITY; GENETIC PREDISPOSITION TO DISEASE; HYPOTENSION; INTERFERON TYPE II; INTERLEUKIN-2; LYSINE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OMEGA-N-METHYLARGININE; ORGANOMETALLIC COMPOUNDS;

EID: 42649085034     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816112e8     Document Type: Article

References (38)

1. Rosenberg SA. Adoptive cellular therapy in patients with advanced cancer: an update. Biol Ther Cancer. 1991;1:1-15.
2. Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988;108:518-523.
3. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989;7:477-485.
4. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907-913.
5. Atzpodien J, Korfer A, Evers P, et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother. 1990;2:18-26.
6. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
7. Anaya JP, Sias JJ. The use of interleukin-2 in human immunodeficiency virus infection. Pharmacotherapy. 2005;25:86-95.
8. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694-704.
9. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 1992;7:417-433.
10. Harada Y, Yahara I. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int Rev Exp Pathol. 1993;34(Pt A):37-55.
11. Queluz TT, Brunda M, Vladutiu AO, et al. Morphological basis of pulmonary edema in mice with cytokine-induced vascular leak syndrome. Exp Lung Res. 1991;17:1095-1108.
12. Mier JW, Aronson FR, Numerof RP, et al. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res. 1988;7:459-476.
13. Mier JW, Vachino G, Van der Meer JWM, et al. Induction of circulating tumor necrosis factor (TNFa) and the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. 1988;8:426-436.
14. Schaafsma MR, Falkenburg JHF, Landegent JE, et al. In vivo production of Interleukin-5, Granulocyte-Macrophage Colony Stimulating Factor, Macrophage Colony Stimulating Factor, and Interleukin-6 during intravenous administration of high-dose Interleukin-2 in cancer patients. Blood. 1991;78:1981-1987.
15. Klausner JM, Goldman G, Skornick Y, et al. Interleukin-2-induced lung permeability is mediated by leukotriene B4. Cancer. 1990;66:2357-2364.
16. Samlowski W, Petersen R, McGregor JR, et al. Evaluation of the superoxide dismutase mimetic M40403 as an adjunct to interleukin 2 based cancer therapy. In: Cuzzocrea S, Salvemini D, eds. Therapeutic Application of Superoxide Dismutase (SOD). Austin: Landes Bioscience; 2004:1-22.
17. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7-20.
18. Hibbs JB Jr, Westenfelder C, Taintor R, et al. Evidence for cytokine inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest. 1992;89:867-877.
19. Ochoa JB, Curti B, Peitzman AB, et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Inst. 1992;84:864-867.
20. Orucevic A, Lala PK. Role of nitric oxide in IL-2 therapy-induced capillary leak syndrome. Cancer Metastasis Rev. 1998;17:127-142.
21. Samlowski WE, Yim C-Y, McGregor JR, et al. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J Immunother. 1995;18:166-178.
22. Moore WM, Webber RK, Jerome GM, et al. L-N6-(1-iminoethyl)-lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem. 1994;37:3886-3888.
23. Fletcher DS, Widmer WR, Luell S, et al. Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J Pharmacol Exp Ther. 1998;284:714-721.
24. Laubach VE, Shesely EG, Smithies O, et al. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA. 1995;92:10688-10692.
25. Yim C-Y, McGregor JR, Kwon O-D, et al. Nitric oxide synthesis contributes to IL-2 induced antitumor responses against intraperitoneal Meth A tumor. J Immunol. 1995;155:4382-4390.
26. Samlowski WE, Petersen R, Cuzzocrea S, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose- limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med. 2003;9:750-755.
27. Granger DL, Taintor RR, Boockvar KS, et al. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996;268:142-151.
28. Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res. 2005;39:797-815.
29. Tsikas D, Gutzki FM, Stichtenoth DO. Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: methods of analysis. Eur J Clin Pharmacol. 2006;62(suppl 13):51-59.
30. Wennmalm A, Benthin G, Edlund A, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res. 1993;73:1121-1127.
31. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-2412.
32. Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int. 1996;55(suppl):S2-S5.
33. Moncada S, Palmer RMJ, Higgs EA. NO: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
34. Kilbourn RG, Gross SS, Jubran A, et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA. 1990;87:3629-3632.
35. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res. 1992;26:48-57.
36. Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med. 2004;2:17.
37. Xia Y, Tsai AL, Berka V, et al. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998;273:25804-25808.
38. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA. 1997;94:6954-6958.